Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2019

View Archived Issues

APPBP2 as a novel therapeutic target in NSCLC

Selective targeting of PARP-2 inhibits AR-positive prostate cancer growth

Myocardial ischemia/reperfusion injury is reduced by prostacyclin analogue-loaded nanoparticles

AAV-eCD4-Ig protects rhesus macaques from SIVmac239 challenges

Commensal Neisseria fight pathogenic relatives in "tribal warfare"

Positive interim data presented for AAV gene therapy in children with CLN6 Batten disease

AZD-0530 shows no statistically significant effect on cerebral metabolic decline in AD

First-in-human data presented for the zwitterionic near-infrared fluorophore ZW800-1

JMJD6 as a novel therapeutic target in neuroblastoma

Rewind Therapeutics to discover drugs for myelin-related neurological diseases

Phase I study of PN-943 demonstrates sustained dose-related target engagement activity

Promedior presents phase II data on PRM-151 in patients with IPF

Zeno Royalties & Milestones patents Bcl-2 inhibitors

Lifesci Pharmaceuticals divulges KLKB1 inhibitors

Momenta Pharmaceuticals launches phase II/III study of nipocalimab in wAIHA

Integral BioSciences discloses new TGFR-1 and MAPK14 inhibitors

Aurigene Discovery Technologies describes new anticancer agents

New glucose-lowering compounds presented by Daiichi Sankyo

First patient dosed in phase IIa study of ABX-464 for the treatment of RA

Prokaryotics receives support for its immune potentiation program

Novartis initiates first-in-human trial of CD19-specific CAR-T cells

Recruitment ongoing in phase I study of BI-754132

T20K demonstrates favorable safety and tolerability in first-in-human study

IDMC recommends stopping PHOCUS study of Pexa-Vec

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....